Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | MMP12 | P39900 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19691246 | 0.85 | GAA (0.65) | GAAALDH1A1MAPTSMYD3POLB | |
| SCHEMBL352186 | 0.84 | ALDH1A1 (0.68) | GAAALDH1A1MAPTSMYD3POLB | |
| SCHEMBL8192718 | 0.83 | ALDH1A1 (0.77) | GAAALDH1A1MAPTSMYD3POLB | |
| SCHEMBL29901720 | 0.83 | ALDH1A1 (0.63) | GAAALDH1A1MAPTSMYD3POLB | |
| SCHEMBL6752 | 0.83 | ALDH1A1 (0.63) | GAAALDH1A1MAPTSMYD3POLB | |
| SCHEMBL31189953 | 0.82 | ALDH1A1 (0.69) | GAAALDH1A1MAPTSMYD3POLB | |
| SCHEMBL532793 | 0.82 | GAA (0.71) | GAAALDH1A1MAPTSMYD3POLB | |
| SCHEMBL3443973 | 0.82 | ALDH1A1 (0.69) | GAAALDH1A1MAPTSMYD3POLB | |
| SCHEMBL531752 | 0.81 | ALDH1A1 (0.67) | GAAALDH1A1MAPTSMYD3POLB | |
| SCHEMBL29195071 | 0.81 | ALDH1A1 (0.65) | GAAALDH1A1MAPTSMYD3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | GAA 1822/4885ALDH1A1 1204/4885MAPT 3644/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | GAA 1374/4885ALDH1A1 1533/4885MAPT 3529/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | GAA 1370/4885ALDH1A1 1575/4885MAPT 3568/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | GAA 1705/4885ALDH1A1 1125/4885MAPT 4031/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | GAA 1428/4885ALDH1A1 1611/4885MAPT 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.